Margaret Rosenfeld, M.D., M.P.H.
Curriculum Vitae
EDUCATION
l983
l988
1995
B.S., Molecular Biophysics and Biochemistry, Yale University,
New Haven, CT. Magna cum laude, Distinction in the Major
M.D., Harvard Medical School, Boston, MA
M.P.H., Department of Epidemiology, University of Washington
School of Public Health, Seattle, WA
POSTGRADUATE TRAINING
l988-91
Internship/Residency in Pediatrics, University of Washington
School of Medicine/Children's Hospital and Medical Center,
Seattle, WA
l992-95
Fellowship, Pediatric Pulmonology, University of Washington
School of Medicine, Seattle, WA
FACULTY POSITIONS HELD
1995-1998
Acting Instructor, Department of Pediatrics, University of
Washington School of Medicine, Seattle, WA
1999-2000
Acting Assistant Professor, Department of Pediatrics, University of
Washington School of Medicine, Seattle, WA
2000Assistant Professor, Department of Pediatrics, University of
Washington School of Medicine, Seattle, WA
HOSPITAL POSITIONS HELD
1995-present Attending Physician, Children’s Hospital and Regional Medical Center,
Seattle, WA
HONORS
1992-98
1993
Leroy Matthews Physician Scientist Award, Cystic Fibrosis
Foundation
Physician Scientist Fellowship Award, Glaxo Corporation
BOARD CERTIFICATION
l993
Diplomate, American Board of Pediatrics
1998
Diplomate in Pediatric Pulmonology
Margaret Rosenfeld, MD, MPH
Page 2
LICENSURE
l988-
State of Washington, # 00027801
PROFESSIONAL ORGANIZATIONS
American Academy of Pediatrics
Washington State Society of Pediatrics
American Thoracic Society
Washington Thoracic Society
Western Society for Pediatric Research
Society for Pediatric Research
Association for Patient Oriented Research
TEACHING RESPONSIBILITIES
Courses:
1991Housestaff noon conference didactic sessions on chronic cough, obstructive
sleep apnea, and common airway disorders (each given annually)
1992Visiting lecturer, NURS 517 (Pediatric Nurse Practitioner graduate course),
University of Washington School of Nursing (annually)
1995Attending physician, housestaff morning report (bi-weekly)
1995Attending rounds didactic sessions to resident ward team on various relevant
topics in pediatric pulmonary medicine (cystic fibrosis, pulmonary physiology,
asthma, bronchiolitis)
1995-2002
Visiting lecturer, Core Pediatrics Clerkship,
University of Washington School of Medicine (~ 6 times annually)
2001
Visiting lecturer, GEN 531 (Genetics graduate seminar)
2002Lecturer, Core Pediatrics Clerkship, ethics session (9 times annually)
2003Lecturer, HuBio 512 course to 1st year medical students (lecture on cystic
fibrosis)
CME:
1. “The Use Of Aerosolized Antibiotics In The Treatment Of CF Children Under Six,” national
teleconference sponsored by Pathogenesis Corp., Seattle, WA, July 19, 2001. Category 1
CME through UWSOM.
2. “Early Intervention in Cystic Fibrosis Lung Disease,” Grand Rounds, CHRMC, 8/23/01.
Trainees:
1997-1999
2000
2001
Graduate thesis preceptor for Toby Lewis, M.D., M.P.H., University of
Washington School of Public Health and Community Medicine
Research mentor for Victoria Cartwright, MD, fellow in Pediatric
Rheumatology, “A Randomized, Controlled Trial of Pain Management
Methods for Intraarticular Steriod Injections in Patients with Juvenile
Rheumatoid Arthritis.”
Research mentor to Chris Goss, MD, MSc, Acting Instructor, Division of
Pulmonary and Critical Care Medicine, Department of Medicine, UWSOM.
Assisted him in preparation of his grant applications to the Cystic Fibrosis
Margaret Rosenfeld, MD, MPH
Page 3
2001
2001-
2002-
2003
Foundation for a LeRoy Matthews Physician Scientist Award and to the NIH
for a K23 award. His proposals assess the quality of life in cystic fibrosis
patients with end-stage lung disease.
Research mentor to Julie Brown, MD, MPH, senior fellow, Division of
Emergency Medicine, “Validation of a Clinical Bronchiolitis Score.” Assisting
in K23 grant application preparation and serving as a member of her research
advisory committee.
Research mentor to Jason Debley, MD, senior fellow, Division of Pulmonary
Medicine. Assisted him in revising his protocol and application for his study
entitled, “The utility of thoracic index to identify high-risk infants following
RSV lower respiratory infection” and in preparing his K23 application to assess
predictors of asthma among wheezy infants.
Advisor to Doris Uh, Pharm.D., postdoctoral fellow, Department of
Pharmaceutics. Mentoring her in investigation of pharmacokinetics of inhaled
antibiotics and supervising her role as consulting clinical pharmacist in the
Division of Pulmonary Medicine.
Research mentor to Martha McKinney, MD, MPH. Assisted her in her
preparing her thesis in fulfillment of the Masters in Public Health degree,
assessing the prevalence of smoking among Canadian asthmatics. Sat on her
thesis committee.
EDITORIAL RESPONSIBILITIES
None
SPECIAL NATIONAL RESPONSIBILITIES
1999Participant in development of Pulmonology subspecialty examination,
American Board of Pediatrics
1999
Correspondent Reviewer, NIDDKM K01 grant application
2001Co-principal investigator, Epidemiologic Study of Cystic Fibrosis
2002Nominating Committee member, Pediatric Assembly, American Thoracic
Society
2002Member American Thoracic Society Health Care Policy Committee
2002Member, Cystic Fibrosis Foundation Therapeutics Development Network
Protocol Review Committee
2002
Manuscript judge, 2003 Uniformed Services Scientific Award Competition
2003Member, Cystic Fibrosis Foundation National Patient Registry Committee
2003Member, American Thoracic Society Pediatric Assembly Planning Committee
SPECIAL LOCAL RESPONSIBILITIES
1997-2000
Subspecialty Teaching Ad Hoc Subcommittee of the Residency Committee,
Children’s Hospital and Regional Medical Center
1997Residency Program Liaison, Division of Pulmonary Medicine, Children’s
Hospital and Regional Medical Center
1998Medical Director, Pulmonary Function Laboratory, Children’s Hospital and
Regional Medical Center
Margaret Rosenfeld, MD, MPH
Page 4
1999, 2002
19992000-2003
2001-2002
2001200120022003-
Reviewer, Cystic Fibrosis Critical Elements of Care Community Provider
Guidelines, Center for Children with Special Needs and Chronic Health
Conditions, CHRMC
Member, Scientific Advisory Committee to the Clinical Research Center, UW
and CHRMC.
Member, UW Clinical Research Training Grant K-30 Steering Committee –
Training Grant Program Track
Member, Newborn Screening Advisory Committee to Washington State Board
of Health regarding additional universal newborn screening tests.
Member, CHRMC Pharmacy and Therapeutics Committee
Member, Medical Advisory Board, World Bike for Breath
Member, Academic Career Advisory Group for UW Pediatric Residents
Co-Fellowship Coordinator, Department of Pediatrics, CHRMC
RESEARCH FUNDING
1.
Cystic Fibrosis Foundation, Leroy Matthew Physician Scientist Award, 1992-1998.
1997-98 budget: $65,250 .
2.
Pari Respiratory Equipment, for Study of Efficacy of Cleaning Methods for SmallVolume Nebulizers, $1,847, 1997.
3.
PathoGenesis Corp., for Safety Study of Aerosolized Tobramycin in Young Children
with Cystic Fibrosis, $90,591, 4/98 – 10/98.
4.
PathoGenesis Corp. and Cystic Fibrosis Foundation, for A Pilot Study of the Deposition
of Inhaled Tobramycin in Young Children with Cystic Fibrosis, 4/99-5/00.. Total award
to Therapeutic Development Network coordinating center and participating sites:
$81,968.
5.
Clinical Associate Physician (CAP) Award K23 RR15529, National Center for
Research Resources, NIH. Award period 5/00 – 4/05. First year annual budget
$103,800.
6.
CHRMC Research Endowment Fund. A pilot study of sputum induction as a noninvasive means to measure serial airway antibiotic concentrations in cystic fibrosis (M.
Rosenfeld, PI). Direct costs $29,800 over 2 years begin in 2002.
7.
Cystic Fibrosis Foundation Clinical Research Grant ROSENF03A0, “Evaluation of
Expiratory Flows from Raised Volumes as Outcome Measures for Clinical Trials in
Infants with Cystic Fibrosis.” Award period: 2003-2006. Total award: $1 million.
Margaret Rosenfeld, MD, MPH
Page 5
Manuscripts in Refereed Journals
1. Rosenfeld M, Ramsey B. Evolution of airway microbiology in the infant with cystic fibrosis:
role of pseudomonal and non-pseudomonal pathogens. Semin Respir Infect 1992;7(3):15867.
2. Rosenfeld M, Cohen M, Ramsey B. Aerosolized antibiotics for bacterial lower airway
infections: principles, efficacy and pitfalls. Clinical Pulmonary Medicine 1997;4(2):101-12.
(Also appeared in Infectious Diseases in Clinical Practice 1998:7;66-79)
3. Rosenfeld M, Davis R, Fitzsimmons S, Pepe M, Ramsey B. The gender gap in cystic fibrosis
mortality. American Journal of Epidemiology 1997;145(9):794-803.
4. Rosenfeld M, Emerson J, Astley S, Joy P, Williams-Warren J, Standaert T, Yim DL, Crist D,
Thykkuttathil J, Torrence M, FitzSimmons S, Ramsey B. Home nebulizer usage among
patients with cystic fibrosis. Journal of Pediatrics 1998;132:125-31.
5. Rosenfeld M, Casey S, Pepe M, Ramsey B. Nutritional effects of long term gastrostomy
feedings in children with cystic fibrosis. Journal of the American Dietetic Association
1999;99:191-4.
6. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy
K, McNamara S, Ramsey B, Wagener J. Diagnostic accuracy of oropharyngeal cultures in
infants and young children with cystic fibrosis. Pediatric Pulmonology, 1999;28:321-328.
7. Rosenfeld M, Pepe MS, Emerson J, Longton G, FitzSimmons S. Effect of different reference
equations on the analysis of pulmonary function data in cystic fibrosis. Pediatric
Pulmonology 2001;31:227-37.
8. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K,
Castile R, Smith AL, Ramsey BW. Longitudinal assessment of Pseudomonas aeruginosa in
young children with cystic fibrosis. Journal of Infectious Disease 2001;183(3):444-452.
9. Rosenfeld M, Emerson J, Willians-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey
BW. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139(3):359-365.
10. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, Hiatt P, McCoy K,
Wilson CB, Inglis A, Smith A, Martin TR, Ramsey BW. Early pulmonary infection,
inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatric Pulmonology
2001;32:356-366.
11. Rosenfeld M, Gibson R, McNamara S, Emerson J, McCoy K, Shell R, Borowitz D, Konstan
M, Retsch-Bogart G, Wilmott RW, Burns JL, Vicini P, Montgomery B, Ramsey B, MD.
Serum and lower respiratory tract drug concentrations produced by tobramycin for inhalation
in young children with cystic fibrosis. J Pediatr 2001;139(4):572-7
12. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas and other
predictors of mortality and morbidity among young children with cystic fibrosis. Pediatr
Pulmonol 2002;34(2):91-100.
13. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic
fibrosis lung transplant referral criteria using predictors of 2-year mortality. American
Journal of Respiratory and Critical Care Medicine 2002;166:1550-5
14. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N,
Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Ramsey
B. Significant microbiologic effect of inhaled tobramycin in young children with cystic
fibrosis. Am J Respir Crit Care Med 2003;167: 841-9.
Margaret Rosenfeld, MD, MPH
Page 6
15. Geller DW, Rosenfeld M, Waltz D, Wilmott R. Efficiency of pulmonary administration of
tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.
Chest 2003; 123:28-36
16. Kulich M., Rosenfeld M., Goss CH, and Wilmott R.. Improved survival among young
patients with cystic fibrosis. J Pediatr 2003:142(6);631-636.
17. Rosenfeld M, Gibson R, Ramsey BW. Pseudomonas acquisition in young patients with cystic
fibrosis: pathophysiology, diagnosis, and management. Curr Opin Pulm Med. 2003
Nov;9(6):492-7.
Book Chapters
1. Marshall S, Rosenfeld M, Ramsey B. Respiratory System: Pediatrics. In Cystic Fibrosis,
Hodson ME, Geddes DM, eds. Chapman and Hall Medical, London, 2000, pp. 204-218.
Other Publications
1. Rosenfeld, M. The gender gap in cystic fibrosis mortality. Thesis submitted in partial
fulfillment of the Masters in Public Health degree, University of Washington, Seattle, WA,
August, 1995.
2. Rosenfeld M, Joy P, Nguyen CD, Burns J. Cleaning home nebulizers used by patients with
cystic fibrosis: is rinsing with tap water enough? Journal of Hospital Infection
2001;49(3):229-30.
Abstracts
1. Rosenfeld M, Ramsey B, Redding G, Castile R, McCoy K, Hiatt P. Changes in pulmonary
function associated with pseudomonal respiratory colonization in infants with cystic fibrosis.
Pediatric Pulmonology 1994;S10:262.
2. Castile R, Rosenfeld M, Drake J, Gadek J, McCoy K, Ramsey B. Relationship of adult-type
lung function tests to bronchoalveolar lavage differential cell counts in infants with cystic
fibrosis. Pediatric Pulmonology 1994;S10:262.
3. Rosenfeld M, Dowd MD, Mueller B. Maternal prenatal alcohol consumption as a risk factor
for sudden infant death syndrome and infant injury death. Presented at Ambulatory
Pediatrics Association meeting, Western Division, February, 1995.
4. Rosenfeld M, Davis R, Pepe M, Ramsey B. Differences in survival by gender among US
cystic fibrosis patients. Pediatric Pulmonology 1995;S12:286.
5. Rosenfeld M. The gender gap in survival in cystic fibrosis. Pediatric Pulmonology
1996;S13:97-98.
6. Joy P, Rosenfeld M, Emerson J, Williams-Warren J, Yim D, Standaert T, Astley S, Torrence
M, FitzSimmons S, Ramsey B. Home nebulizer usage among CF patients. Pediatric
Pulmonology 1996;S13;309.
7. Rosenfeld M, Accurso F, Armstrong D,Castile R, Emerson J, Grimwood K, Hiatt P, McCoy
K, Ramsey B, Wagener J. The diagnostic accuracy of oropharyngeal cultures relative to
lower airway cultures in infants and young children with cystic fibrosis. Pediatric
Pulmonology 1997;S14;295.
8. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Ramsey B. Defining a pulmonary
exacerbation in cystic fibrosis. Pediatric Pulmonology 1997;S14;295.
Margaret Rosenfeld, MD, MPH
Page 7
9. Rosenfeld M, Pepe M, Emerson J, FitzSimmons S. Effect of different reference equations on
the analysis of pulmonary function data in CF. Pediatric Pulmonology 1998;S15,333.
10. Emerson J, Pepe M, Rosenfeld M, FitzSimmons S. Prognostic indicators in children with
cystic fibrosis. Pediatric Pulmonology 1998;S15,403.
11. Ramsey B, McNamara S, Gibson R, Emerson J, Rosenfeld M, Hiatt P, McConnell R, McCoy
K, Lawrence C, Olson P. P. aeruginosa (Pa) Colonization in Young Children with Cystic
Fibrosis. Pediatric Pulmonology 1998;S15,320.
12. Rosenfeld M, Borowitz D, Emerson J, Gibson R, McCoy K, McNamara S, Montgomery B,
Ramsey B, Vicini P, Wilmott B. Safety and serum pharmacokinetics of inhaled tobramycin in
very young CF patients. Pediatric Pulmonology 1999;S19,262.
13. Lewis TC, Rosenfeld M, Gibson R, Ramsey B. Urban/rural differences in specialty health
care utilization and health outcomes in cystic fibrosis. Pediatric Pulmonology 1999;S19,367.
14. Vicini P, Rosenfeld M, Borowitz D, Emerson J, Gibson R, McCoy K, McNamara S,
Montgomery B, Ramsey B, Wilmott B. Population pharmacokinetics of inhaled tobramycin
in CF patients <6 years of age. PharmSci 1999; S1(4): 1602-1603.
15. Rosenfeld M., Mayer Hamblett N., Goss C.H., Aitken M.L., Emerson J., Kronmal R..
Predictors of two year mortality in CF. Pediatric Pulmonology 2000; supp 20; 316.
16. Rosenfeld M, Burns JL, Joy P, Nguyen C, Krzewinski J. Cleaning home nebulizers: Is water
enough? . Pediatric Pulmonology 2000: supp 20;291.
17. Rosenfeld M, Gibson R, McNamara S, Emerson J, Burns JL, Castile R, Hiatt P, McCoy K,
Wilson CB, Smith A, Ramsey BW. Early course of pulmonary infection, inflammation and
clinical outcomes in infants with cystic fibrosis. Pediatric Pulmonology 2000: supp 20;112113.
18. Wilmott, RW, Charfield B, Dyson, M, Geller D, Milgram L, Noone PG, Rodman D,
Rosenfeld M, Waltz DA, Schaeffler B, Challoner P. Aerodose improves TOBI delivery in
cystic fibrosis. Pediatric Pulmonology 2001: supp 22;292.
19. Goss CH, Kulich M, Rosenfeld M, Waltz DA, Wilmott RW. Most of the recent gains in
survival in CF in the US have been in children ages 2-16 years. American Journal of
Respiratory and Critical Care Medicine 2002:165 (8);A651.
20. Gibson RL, Emerson, J, McNamara S, Burns J, Rosenfeld M, Yunker A, Hamblett N,
Accurso F, Dovery M, Hiatt P, Moss R, Konstan M, Retsch-Bogart G, Waltz D, Wilmott R,
Wagener J, Zeitlin P, Ramsey B. A randomized, controlled trial of inhaled tobramycin in
young children with cystic fibrosis: eradication of Pseudomonas from the lower airway.
Pediatr Pulmonol 2002:s24;300
21. Campbell J, Kulich M, Rosenfeld M, Kronmal R. Pulmonary function reference curves for
cystic fibrosis patients. Pediatr Pulmonol 2002:s24;332.
22. Rosenfeld M, Emerson J, McNamara S, Castile R, McCoy K, Hiatt P, Burns JL, Gibson R,
Ramsey BW. Longitudinal followup of Pseudomonas aeruginosa infection in young children
with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2003
(abstract, in press).
23. Gibson RL, Emerson J, McNarmara S, Burns JL, Rosenfeld M, Hamblett N, Acton J,
Borowitz D, Hiatt P, Konstan MW, Moss R, Restsch-Bogart G, Wagener J. Duration of the
anti-pseudomonal treatment effect of inhaled tobramycin in young children with cystic
fibrosis. Pediatr Pulmonol 2003; s25:295.
Margaret Rosenfeld, MD, MPH
Page 8
24. Rosenfeld M, Caron H, Emerson J, Hamblett N, Burns JL, Gibson R, McNamara S, Hiatt P,
McCoy K, Castile R, Ramsey B. What effect do anti-pseudomonal antibiotics have on serial
upper airway cultures in infants with CF? Pediatr Pulmonol 2003; s25:313.
25. Sagel SD, Emerson J, Rosenfeld M, McNamara S, Caron H, Ramsey B, Wagener J, Gibson
R. Association of upper versus lower airway Pseudomonas aeruginosa infection with
endobronchial inflammation and clinical status in young children with CF. Pediatr Pulmonol
2003; s25:313
OTHER
Local invitational lectures
1. CF and Gene Therapy Investigator Seminars Series presentation “Gender Gap in Cystic
Fibrosis Mortality,” July, 1997
2. “Newborn Screening for Cystic Fibrosis,” CF Annual Clinical Conference, Urban
Horticulture Center, July 10, 1998
3. “Newborn screening for CF”, Annual Northwest CF Clinical Conference, Urban Horticulture
Center, Seattle, July, 1998
4. “Predictors of Two Year Survival in Cystic Fibrosis,” presentation to the UW CF
Epidemiology-Biostatistics Working Group, 1/00
5. “Cystic fibrosis: new modalities of therapy,” Graduate Division, UW School of Dentistry,
4/25/00
6. “Predicting survival in CF,” Presentation at CHRMC quarterly CF clinical conference, 1/01.
7. “Evaluation of Pulmonary Function Tests from Raised Lung Volumes as Outcome Measures
for Clinical Trials in Infants with Cystic Fibrosis,” presentation to the UW CF EpidemiologyBiostatistics Working Group, 1/01
9. “Predicting survival in CF.” Presentation at CHRMC quarterly CF clinical conference, 1/01.
8. “Recurrent Wheezing in Infants: Diagnosis and Management,” National Initiative for
Children’s Health Quality Asthma Quality Improvement Conference, Seattle, 4/6/01 (invited
by Jim Stout, MD, and Lenna Liu, MD).
9. “Diagnosis of Management of the Wheezy Infant.” WWAMI Visiting Professor, Madrona
Pediatrics Group, Bellingham, WA, July 18, 2001
10. “First Isolation of Pseudomonas aeruginosa: To Treat or Not To Treat?” Annual Northwest
Regional Cystic Fibrosis Clinical Conference, Center for Urban Horticulture, Seattle.
11. “Early Intervention in Cystic Fibrosis Lung Disease.” Grand Rounds, CHRMC, Aug 23,
2001.
12. “Predictors of 2-year survival in CF.” UW CF Epidemiology / Biostatistics Working Group,
Center for Urban Horticulture, 10/01.
13. “Predicting Short-Term Survival in Cystic Fibrosis,” Cystic Fibrosis And Gene Therapy
Research Center Investigator’s Seminar Series, 2/11/02
14. “Developing Better Criteria for Lung Transplant Referral,” UW CF
Epidemiology/Biostatistics Working Group, Center for Urban Horticulture, 7/03
15. “New Lung Function Tests in Infants with CF,” Cystic Fibrosis Clinical Conference, Center
for Urban Horticulture, 9/03
Margaret Rosenfeld, MD, MPH
Page 9
16. “Designing and Participating in Multicenter Clinical Trials: an Investigator’s Perspective,”
Pediatric Clinical Research Center forum on Practical Aspects of Conducting Pediatric
Clinical Research Trials, CHRMC, 10/27/03
17. “Lung Function Testing in Infants: Promising New Methods,” CHRMC Grand Rounds,
12/4/03
National invitational lectures
“Safety and lower respiratory tract deposition of inhaled tobramycin in very young children
with CF” Symposium presentation, North American Cystic Fibrosis Conference, Seattle,
WA, October, 1999
2. “Gender differences in cystic fibrosis” Nutritionists’ workshop, North American Cystic
Fibrosis Conference, Seattle, WA, October, 1999
3. Early CF lung disease and preliminary studies of the use of tobramycin for inhalation in
infants with CF. Presentations at Phoenix Children’s Hospital and University of California,
San Francisco, 10/00.
4. “Epidemiology as a Research Tool in Cystic Fibrosis,” co-director, Short Course, North
American Cystic Fibrosis Foundation Annual Conference, 11/00, Baltimore, MD and 10/02,
New Orleans, LA.
5. “Early infection, inflammation and clinical outcomes in infants with CF.” Symposium
presentation, North American Cystic Fibrosis Foundation Annual Conference, 11/00,
Baltimore, MD.
6. “The Use Of Tobramycin For Inhalation In Children With Cystic Fibrosis <6 Years Of Age.”
Invited presentation at symposium on “Decisions facing the CF clinician at first
Pseudomonas aeruginosa isolation,” Royal College of Physicians, London, July 6, 2001.
7. “The use of aerosolized antibiotics in the treatment of cystic fibrosis children under six,”
CME teleconference sponsored by University of Washington and BioScience
Communications, Inc.
8. “Early intervention in CF lung disease: completed research and current controversies." North
American Cystic Fibrosis Foundation Conference, Orlando, FL, 10/01.
9. “Why is Asthma on the Rise?” Central Ohio Pediatrics Society, Columbus, OH, 2/20/02
10. “Early Intervention in Cystic Fibrosis Lung Disease: Balancing Benefits and Risks,” Grand
Rounds, Columbus Children’s Hospital, Columbus, OH, 2/21/02
11. “The Wheezy Infant: Diagnosis and Management,” noontime presentation, Columbus
Children’s Hospital, Columbus, OH, 2/21/02
12. “Longitudinal followup of Pseudomonas aeruginosa infection in young children with cystic
fibrosis,” American Thoracic Society International Conference, Seattle, WA, May, 2003.
13. “What effect do anti-pseudomonal antibtiocs have on serial upper airway cutltues in infant
with CF?” Workshop presentation at 2003 North American Cystic Fibrosis Foundation
Annual Conference, Anaheim, October, 2003
14. “Dilemmas regarding lung transplant referral criteria,” Expert discussant, Physician Grand
Rounds, 2003 North American Cystic Fibrosis Foundation Annual Conference, Anaheim,
October, 2003
15. “Overview of published evidence on outcomes with early detection,” 2003 Newborn
Screening for Cystic Fibrosis Meeting, sponsored by the National Center on Birth Defects
1.
Margaret Rosenfeld, MD, MPH
Page 10
and Developmental Disbilities at the Centers for Disease Control and the Cystic Fibrosis
Foundation, Atlanta, November 20, 2003